|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 100 DAINGERFIELD ROAD |
Address2 | |
City | ALEXANDRIA |
State | VA |
Zip Code | 22314 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 27478-12
|
||||||||
|
6. House ID# 303540000
|
TYPE OF REPORT | 8. Year | 2008 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Charles B. Sewell, Senior Vice President, Government Affairs |
Date | 07/17/2008 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
I. HR 971, the "Community Pharmacy Fairness Act of 2007"; S. 2161, the "Community Pharmacy Fairness Act of 2007"; CMS-2238-P, CMS-2238-FC and CMS-2238-IFC, the proposed, final rule, and interim final rule re implementation the Medicaid provisions of the Deficit Reduction Act of 2005;
CMS-1270F, Final rule implementing the competitive acquisition program requirements for Durable Medical Equipment Prosthetics, Orthotics and Supplies; HR 2900, provision related to pedigree requirements; HR 4 and S.3, the "Medicare Prescription Drug Price Negotiation Act of 2007"; potential language not included in S. 2499, the "Medicare, Medicaid and SCHIP Extension Act of 2007" re e-prescribing; HR 1474, the "Fair and Speedy Treatment (FAST) of Medicare Prescription Drug Claims Act of 2007; CMS-6006-P, proposed rule requring a surety bond for all Medicare DMEPOS providers; Sec. 913 of FDAAA of 2007, relating to development of a standard numerical drug identifier; and HR 5839, the "Safeguarding America's Pharmaceuticals Act of 2008," provisions relating to imposition of pedigree and track and trace requirements upon community pharmacy;
II. and also HR 3140, "Saving Our Community Pharmacies Act of 2007"; S. 1951, the "Fair Medicaid Drug Payment Act of 2007"; S. 1954, the "Pharmacy Access Improvement (PhAIm) Act of 2007"; HR 3700, the "Fair Medicaid Drug Payment Act of 2007"; Sec. 7002(b) of HR 2006 and PL 110-28, "Requirements for Use of Tamper-Resistant Prescription Pads Under the Medicaid Program", (the U.S. Troop Readiness, Veterans' Care, Katrina Recovery, and Iraq Accountability Appropriations Act of 2007); PL 110-181 -- HR 1585, HR 4986 and S. 1547, National Defense Authorization Act for Fiscal Year 2008, provisions related to pharmacy payment - sections 703 and 702 of HR 1585 and HR 4986 and Sec. 701 of S. 1547, HR 6357, the "PRO(TECH)T Act of 2008", provisions impacting health technology requirements for pharmacies; HR 6331, the "Medicare Improvements for Patients and Prviders Act of 2008," Sec. 154 related to Medicare DMEPOS competitive acquisition program, Sec. 171 related to prompt payment of Part D reimbursements to pharmacies, Sec. 203, related to pharmacy reimbursement under Medicaid,
all of II. done separately and as joint project with the National Association of Chain Drug Stores for the Coalition for Community Pharmacy Action.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Defense - Dept of (DOD), Drug Enforcement Administration (DEA), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Sewell |
|
|
|
Tony |
Lee |
|
|
|
Anne |
Cassity |
|
|
|
Jim |
Hippe |
|
|
|
Gary |
Haulmark |
|
|
|
Chris |
Parinello |
|
|
|
Thomas |
Riddleberger |
|
|
|
Brian |
Anderson |
|
|
|
Elizabeth |
Bartlett |
|
|
|
Christopher |
Nave |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |